Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid
- This topic has 0 replies, 1 voice, and was last updated 3 years, 11 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.
https://meetinglibrary.asco.org/record/185089/abstract
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.